Advanced Search

Project: Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update

Public Report Complete



Project Summary

Title and Description


Key Questions


Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Stroke Extraction Kathryn Lallinger 1, 2, 3


Associated Studies (each link opens a new tab)

Title Author Year
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Gage BF., Waterman AD., Shannon W., Boechler M., Rich MW., Radford MJ. 2001
Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Stoddard MF., Singh P., Dawn B., Longaker RA. 2003
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. Wang TJ., Massaro JM., Levy D., Vasan RS., Wolf PA., D'Agostino RB., Larson MG., Kannel WB., Benjamin EJ. 2003
Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. Stöllberger C., Chnupa P., Abzieher C., Länger T., Finsterer J., Klem I., Hartl E., Wehinger C., Schneider B. 2004
Utility of transesophageal echocardiography in identification of thrombogenic milieu in patients with atrial fibrillation (an ACUTE ancillary study). Thambidorai SK., Murray RD., Parakh K., Shah TK., Black IW., Jasper SE., Li J., Apperson-Hansen C., Asher CR., Grimm RA., Klein AL. 2005
Predicting embolic events in patients with nonvalvular atrial fibrillation: evaluation of the CHADS2 score in a Mediterranean population. Ruiz Ortiz M., Romo E., Mesa D., Delgado M., Anguita M., López Granados A., Castillo JC., Arizón JM., Suárez de Lezo J. 2008
Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. Fang MC., Go AS., Chang Y., Borowsky L., Pomernacki NK., Singer DE. 2008
Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Rietbrock S., Heeley E., Plumb J., van Staa T. 2008
Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Morgan CL., McEwan P., Tukiendorf A., Robinson PA., Clemens A., Plumb JM. 2009
Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Poli D., Antonucci E., Grifoni E., Abbate R., Gensini GF., Prisco D. 2009
Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors. Crandall MA., Horne BD., Day JD., Anderson JL., Muhlestein JB., Crandall BG., Weiss JP., Osborne JS., Lappé DL., Bunch TJ. 2009
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Lip GY., Nieuwlaat R., Pisters R., Lane DA., Crijns HJ. 2010
Thromboembolism in patients with atrial fibrillation with and without left atrial thrombus documented by transesophageal echocardiography. Nair CK., Holmberg MJ., Aronow WS., Shen X., Li H., Lakkireddy D. -- Not Found --
Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population. Poli D., Lip GY., Antonucci E., Grifoni E., Lane D. 2011
Left atrial appendage dimensions predict the risk of stroke/TIA in patients with atrial fibrillation. Beinart R., Heist EK., Newell JB., Holmvang G., Ruskin JN., Mansour M. 2011
The CHADS score role in managing anticoagulation after surgical ablation for atrial fibrillation. Ad N., Henry L., Schlauch K., Holmes SD., Hunt S. 2010
A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. Van Staa TP., Setakis E., Di Tanna GL., Lane DA., Lip GY. 2011
Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. Olesen JB., Lip GY., Hansen ML., Hansen PR., Tolstrup JS., Lindhardsen J., Selmer C., Ahlehoff O., Olsen AM., Gislason GH., Torp-Pedersen C. 2011
Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study. Potpara TS., Polovina MM., Licina MM., Marinkovic JM., Prostran MS., Lip GY. 2012
The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Olesen JB., Torp-Pedersen C., Hansen ML., Lip GY. 2012
Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study. Larsen TB., Lip GY., Skjøth F., Due KM., Overvad K., Hvilsted Rasmussen L. 2012
Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Olesen JB., Lip GY., Lane DA., Køber L., Hansen ML., Karasoy D., Hansen CM., Gislason GH., Torp-Pedersen C. 2012
Efficacy of the CHADS₂ scoring system to assess left atrial thrombogenic milieu risk before cardioversion of non-valvular atrial fibrillation. Yarmohammadi H., Klosterman T., Grewal G., Alraies MC., Varr BC., Lindsay B., Zurick AO., Shrestha K., Tang WH., Bhargava M., Klein AL. 2013
A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. Singer DE., Chang Y., Borowsky LH., Fang MC., Pomernacki NK., Udaltsova N., Reynolds K., Go AS. 2013
Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation? Abraham JM., Larson J., Chung MK., Curtis AB., Lakshminarayan K., Newman JD., Perez M., Rexrode K., Shara NM., Solomon AJ., Stefanick ML., Torner JC., Wilkoff BL., Wassertheil-Smoller S. 2013
Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Forslund T., Wettermark B., Wändell P., von Euler M., Hasselström J., Hjemdahl P. 2014
Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. Bonde AN., Lip GY., Kamper AL., Hansen PR., Lamberts M., Hommel K., Hansen ML., Gislason GH., Torp-Pedersen C., Olesen JB. 2014
Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database. van den Ham HA., Klungel OH., Singer DE., Leufkens HG., van Staa TP. 2015
Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation. Abumuaileq RR., Abu-Assi E., López-López A., Raposeiras-Roubin S., Rodríguez-Mañero M., Martínez-Sande L., García-Seara J., Fernandez-López XA., Peña-Gil C., González-Juanatey JR. 2015
Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. Ashburner JM., Go AS., Chang Y., Fang MC., Fredman L., Applebaum KM., Singer DE. 2016
Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Philippart R., Brunet-Bernard A., Clementy N., Bourguignon T., Mirza A., Angoulvant D., Babuty D., Lip GY., Fauchier L. 2016
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Hijazi Z., Lindbäck J., Alexander JH., Hanna M., Held C., Hylek EM., Lopes RD., Oldgren J., Siegbahn A., Stewart RA., White HD., Granger CB., Wallentin L. 2016
Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated? Fauchier L., Clementy N., Bisson A., Ivanes F., Angoulvant D., Babuty D., Lip GY. 2016
Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Nielsen PB., Larsen TB., Skjøth F., Overvad TF., Lip GY. 2016
Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care. Allan V., Banerjee A., Shah AD., Patel R., Denaxas S., Casas JP., Hemingway H. 2017
Bleeding Risk Index in an anticoagulation clinic. Assessment by indication and implications for care. Aspinall SL., DeSanzo BE., Trilli LE., Good CB. 2005
Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Gage BF., Yan Y., Milligan PE., Waterman AD., Culverhouse R., Rich MW., Radford MJ. 2006
Development of a contemporary bleeding risk model for elderly warfarin recipients. Shireman TI., Mahnken JD., Howard PA., Kresowik TF., Hou Q., Ellerbeck EF. 2006
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Pisters R., Lane DA., Nieuwlaat R., de Vos CB., Crijns HJ., Lip GY. 2010
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. Fang MC., Go AS., Chang Y., Borowsky LH., Pomernacki NK., Udaltsova N., Singer DE. 2011
Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Gallego P., Roldán V., Torregrosa JM., Gálvez J., Valdés M., Vicente V., Marín F., Lip GY. 2012
Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Roldán V., Marín F., Fernández H., Manzano-Fernandez S., Gallego P., Valdés M., Vicente V., Lip GYH. 2013
The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience. Barnes GD., Gu X., Haymart B., Kline-Rogers E., Almany S., Kozlowski J., Besley D., Krol GD., Froehlich JB., Kaatz S. 2014
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. O'Brien EC., Simon DN., Thomas LE., Hylek EM., Gersh BJ., Ansell JE., Kowey PR., Mahaffey KW., Chang P., Fonarow GC., Pencina MJ., Piccini JP., Peterson ED. 2015
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Hijazi Z., Oldgren J., Lindbäck J., Alexander JH., Connolly SJ., Eikelboom JW., Ezekowitz MD., Held C., Hylek EM., Lopes RD., Siegbahn A., Yusuf S., Granger CB., Wallentin L. 2016
Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists. Jaspers Focks J., van Vugt SP., Albers-Akkers MT., Lamfers EJ., Bloem-de Vries LM., Verheugt FW., Brouwer MA. 2016
Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients? Esteve-Pastor MA., García-Fernández A., Macías M., Sogorb F., Valdés M., Roldán V., Muñiz J., Badimon L., Roldán I., Bertomeu-Martínez V., Cequier Á., Lip GY., Anguita M., Marín F. 2016
Comparison of the CHA Yao X., Gersh BJ., Sangaralingham LR., Kent DM., Shah ND., Abraham NS., Noseworthy PA. 2017
Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Rivera-Caravaca JM., Roldán V., Esteve-Pastor MA., Valdés M., Vicente V., Lip GYH., Marín F. 2017
The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants. Lip GYH., Skjøth F., Nielsen PB., Kjældgaard JN., Larsen TB. 2018
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Berge E., Abdelnoor M., Nakstad PH., Sandset PM. 2000
Atrial fibrillation or flutter and stroke: a Danish population-based study of the effectiveness of oral anticoagulation in clinical practice. Frost L., Johnsen SP., Pedersen L., Toft E., Husted S., Sørensen HT. 2002
The safety of low-molecular weight heparins for the prevention of thromboembolic events after cardioversion of atrial fibrillation. Yigit Z., Küçükoglu MS., Okçün B., Sansoy V., Güzelsoy D. 2003
Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Stellbrink C., Nixdorff U., Hofmann T., Lehmacher W., Daniel WG., Hanrath P., Geller C., Mügge A., Sehnert W., Schmidt-Lucke C., Schmidt-Lucke JA. 2004
Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Lorenzoni R., Lazzerini G., Cocci F., De Caterina R. 2004
Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Shireman TI., Howard PA., Kresowik TF., Ellerbeck EF. 2004
Primary prevention of arterial thromboembolism in the oldest old with atrial fibrillation--a randomized pilot trial comparing adjusted-dose and fixed low-dose coumadin with aspirin. Vemmos KN., Tsivgoulis G., Spengos K., Manios E., Xinos K., Vassilopoulou S., Zakopoulos N., Moulopoulos S. 2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., Chrolavicius S., Pfeffer M., Hohnloser S., Yusuf S. 2006
A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Rash A., Downes T., Portner R., Yeo WW., Morgan N., Channer KS. 2007
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Mant J., Hobbs FD., Fletcher K., Roalfe A., Fitzmaurice D., Lip GY., Murray E. 2007
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Ezekowitz MD., Reilly PA., Nehmiz G., Simmers TA., Nagarakanti R., Parcham-Azad K., Pedersen KE., Lionetti DA., Stangier J., Wallentin L. 2007
Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Hart RG., Bhatt DL., Hacke W., Fox KA., Hankey GJ., Berger PB., Hu T., Topol EJ. 2008
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. Connolly SJ., Pogue J., Hart RG., Hohnloser SH., Pfeffer M., Chrolavicius S., Yusuf S. 2009
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Holmes DR., Reddy VY., Turi ZG., Doshi SK., Sievert H., Buchbinder M., Mullin CM., Sick P. 2009
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Weitz JI., Connolly SJ., Patel I., Salazar D., Rohatagi S., Mendell J., Kastrissios H., Jin J., Kunitada S. 2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Hansen ML., Sørensen R., Clausen MT., Fog-Petersen ML., Raunsø J., Gadsbøll N., Gislason GH., Folke F., Andersen SS., Schramm TK., Abildstrøm SZ., Poulsen HE., Køber L., Torp-Pedersen C. 2010
Apixaban in patients with atrial fibrillation. Connolly SJ., Eikelboom J., Joyner C., Diener HC., Hart R., Golitsyn S., Flaker G., Avezum A., Hohnloser SH., Diaz R., Talajic M., Zhu J., Pais P., Budaj A., Parkhomenko A., Jansky P., Commerford P., Tan RS., Sim KH., Lewis BS., Van Mieghem W., Lip GY., Kim JH., Lanas-Zanetti F., Gonzalez-Hermosillo A., Dans AL., Munawar M., O'Donnell M., Lawrence J., Lewis G., Afzal R., Yusuf S. 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. Patel MR., Mahaffey KW., Garg J., Pan G., Singer DE., Hacke W., Breithardt G., Halperin JL., Hankey GJ., Piccini JP., Becker RC., Nessel CC., Paolini JF., Berkowitz SD., Fox KA., Califf RM. 2011
Apixaban versus warfarin in patients with atrial fibrillation. Granger CB., Alexander JH., McMurray JJ., Lopes RD., Hylek EM., Hanna M., Al-Khalidi HR., Ansell J., Atar D., Avezum A., Bahit MC., Diaz R., Easton JD., Ezekowitz JA., Flaker G., Garcia D., Geraldes M., Gersh BJ., Golitsyn S., Goto S., Hermosillo AG., Hohnloser SH., Horowitz J., Mohan P., Jansky P., Lewis BS., Lopez-Sendon JL., Pais P., Parkhomenko A., Verheugt FW., Zhu J., Wallentin L. 2011
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. Fosbol EL., Wang TY., Li S., Piccini JP., Lopes RD., Shah B., Mills RM., Klaskala W., Alexander KP., Thomas L., Roe MT., Peterson ED. 2012
A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. Azoulay L., Dell'Aniello S., Simon TA., Langleben D., Renoux C., Suissa S. 2012
Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience. Chun KR., Bordignon S., Urban V., Perrotta L., Dugo D., Fürnkranz A., Nowak B., Schmidt B. 2013
Edoxaban versus warfarin in patients with atrial fibrillation. Giugliano RP., Ruff CT., Braunwald E., Murphy SA., Wiviott SD., Halperin JL., Waldo AL., Ezekowitz MD., Weitz JI., Špinar J., Ruzyllo W., Ruda M., Koretsune Y., Betcher J., Shi M., Grip LT., Patel SP., Patel I., Hanyok JJ., Mercuri M., Antman EM. 2013
Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. Larsen TB., Rasmussen LH., Gorst-Rasmussen A., Skjøth F., Rosenzweig M., Lane DA., Lip GY. 2014
Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Larsen TB., Gorst-Rasmussen A., Rasmussen LH., Skjøth F., Rosenzweig M., Lip GY. 2014
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Laliberté F., Cloutier M., Nelson WW., Coleman CI., Pilon D., Olson WH., Damaraju CV., Schein JR., Lefebvre P. 2014
Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Nelson WW., Song X., Coleman CI., Thomson E., Smith DM., Damaraju CV., Schein JR. 2014
Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. Holmes DR., Kar S., Price MJ., Whisenant B., Sievert H., Doshi SK., Huber K., Reddy VY. 2014
Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Vaughan Sarrazin MS., Jones M., Mazur A., Chrischilles E., Cram P. 2014
Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Larsen TB., Rasmussen LH., Gorst-Rasmussen A., Skjøth F., Lane DA., Lip GY. 2014
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Graham DJ., Reichman ME., Wernecke M., Zhang R., Southworth MR., Levenson M., Sheu TC., Mott K., Goulding MR., Houstoun M., MaCurdy TE., Worrall C., Kelman JA. 2015
Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation. Gloekler S., Shakir S., Doblies J., Khattab AA., Praz F., Guerios Ê., Koermendy D., Stortecky S., Pilgrim T., Buellesfeld L., Wenaweser P., Windecker S., Moschovitis A., Jaguszewski M., Landmesser U., Nietlispach F., Meier B. 2015
Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users. Laliberté F., Cloutier M., Crivera C., Nelson WW., Olson WH., Schein J., Vanderpoel J., Germain G., Lefebvre P. 2015
Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. Lip GY., Skjøth F., Rasmussen LH., Larsen TB. 2015
Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: Understanding the differences in the location and type of leaks and their clinical implications. Pillarisetti J., Reddy YM., Gunda S., Swarup V., Lee R., Rasekh A., Horton R., Massumi A., Cheng J., Bartus K., Badhwar N., Han F., Atkins D., Bommana S., Earnest M., Nath J., Ferrell R., Bormann S., Dawn B., Di Biase L., Mansour M., Natale A., Lakkireddy D. 2015
Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. Lauffenburger JC., Farley JF., Gehi AK., Rhoney DH., Brookhart MA., Fang G. 2015
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. Abraham NS., Singh S., Alexander GC., Heien H., Haas LR., Crown W., Shah ND. 2015
Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. Staerk L., Gislason GH., Lip GY., Fosbøl EL., Hansen ML., Lamberts M., Bonde AN., Torp-Pedersen C., Olesen JB. 2015
Risk of Stroke and Death in Atrial Fibrillation by Type of Anticoagulation: A Propensity-Matched Analysis. Leef G., Qin D., Althouse A., Alam MB., Rattan R., Munir MB., Patel D., Khattak F., Vaghasia N., Adelstein E., Jain SK., Saba S. 2015
Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Nelson WW., Song X., Thomson E., Smith DM., Coleman CI., Damaraju CV., Schein JR. 2015
Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Lip GY., Skjøth F., Nielsen PB., Larsen TB. 2015
Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Martinez C., Katholing A., Wallenhorst C., Freedman SB. 2016
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Villines TC., Schnee J., Fraeman K., Siu K., Reynolds MW., Collins J., Schwartzman E. 2015
Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Seeger JD., Bykov K., Bartels DB., Huybrechts K., Zint K., Schneeweiss S. 2015
Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation. Avgil Tsadok M., Jackevicius CA., Rahme E., Humphries KH., Pilote L. 2015
Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin. Fonseca E., Sander SD., Hess GP., Ghosh S. 2015
REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation--The RELIEF study. Coleman CI., Antz M., Ehlken B., Evers T. 2016
Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Forslund T., Wettermark B., Hjemdahl P. 2016
An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Deitelzweig S., Bruno A., Trocio J., Tate N., Gupta K., Lin J., Lingohr-Smith M. 2016
Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Beyer-Westendorf J., Ehlken B., Evers T. 2016
Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Gorst-Rasmussen A., Lip GY., Bjerregaard Larsen T. 2016
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Larsen TB., Skjøth F., Nielsen PB., Kjældgaard JN., Lip GY. 2016
Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States. Coleman CI., Tangirala M., Evers T. 2016
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Yao X., Abraham NS., Sangaralingham LR., Bellolio MF., McBane RD., Shah ND., Noseworthy PA. 2016
Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. Björck F., Renlund H., Lip GY., Wester P., Svensson PJ., Själander A. 2016
Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States. Lip GY., Pan X., Kamble S., Kawabata H., Mardekian J., Masseria C., Bruno A., Phatak H. 2016
Left atrial appendage closure: A single center experience and comparison of two contemporary devices. Figini F., Mazzone P., Regazzoli D., Porata G., Ruparelia N., Giannini F., Stella S., Ancona F., Agricola E., Sora N., Marzi A., Aurelio A., Trevisi N., Della Bella P., Colombo A., Montorfano M. 2017
Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Coleman CI., Antz M., Bowrin K., Evers T., Simard EP., Bonnemeier H., Cappato R. 2016
Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. Johnson ME., Lefèvre C., Collings SL., Evans D., Kloss S., Ridha E., Maguire A. 2016
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Halvorsen S., Ghanima W., Fride Tvete I., Hoxmark C., Falck P., Solli O., Jonasson C. 2017
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. Graham DJ., Reichman ME., Wernecke M., Hsueh YH., Izem R., Southworth MR., Wei Y., Liao J., Goulding MR., Mott K., Chillarige Y., MaCurdy TE., Worrall C., Kelman JA. 2016
Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Staerk L., Fosbøl EL., Lip GYH., Lamberts M., Bonde AN., Torp-Pedersen C., Ozenne B., Gerds TA., Gislason GH., Olesen JB. 2017
Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation. Brown JD., Shewale AR., Talbert JC. 2016
Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation. McHorney CA., Peterson ED., Laliberté F., Germain G., Nelson WW., Crivera C., Schein J., Lefebvre P. 2016
Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database. Giner-Soriano M., Roso-Llorach A., Vedia Urgell C., Castells X., Capellà D., Ferreira-González I., Elorza-Ricart JM., Casajuana M., Troncoso Mariño A., Diògene E., Bolíbar B., Violan C., Morros R. 2017
Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. Bengtson LGS., Lutsey PL., Chen LY., MacLehose RF., Alonso A. 2017
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Noseworthy PA., Yao X., Abraham NS., Sangaralingham LR., McBane RD., Shah ND. 2016
Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Abraham NS., Noseworthy PA., Yao X., Sangaralingham LR., Shah ND. 2017
Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Monaco L., Biagi C., Conti V., Melis M., Donati M., Venegoni M., Vaccheri A., Motola D. 2017
Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Forslund T., Wettermark B., Andersen M., Hjemdahl P. 2018
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Nielsen PB., Skjøth F., Søgaard M., Kjældgaard JN., Lip GY., Larsen TB. 2017
Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. Lamberts M., Staerk L., Olesen JB., Fosbøl EL., Hansen ML., Harboe L., Lefevre C., Evans D., Gislason GH. 2017
Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Hohnloser SH., Basic E., Nabauer M. 2017
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients. Li XS., Deitelzweig S., Keshishian A., Hamilton M., Horblyuk R., Gupta K., Luo X., Mardekian J., Friend K., Nadkarni A., Pan X., Lip GYH. 2017
Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation. Contreras Muruaga MDM., Vivancos J., Reig G., González A., Cardona P., Ramírez-Moreno JM., Martí J., Suárez Fernández C. 2017
Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban. Coleman C., Yuan Z., Schein J., Crivera C., Ashton V., Laliberté F., Lefebvre P., Peterson ED. 2017
Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice. Coleman CI., Peacock WF., Antz M. 2018
Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. Weir MR., Berger JS., Ashton V., Laliberté F., Brown K., Lefebvre P., Schein J. 2017
Real-practice thromboprophylaxis in atrial fibrillation. Deambrosis P., Bettiol A., Bolcato J., Pirolo R., Franchin G., Themistoclakis S., Pellizzari M., Chinellato A., Giusti P. 2017
Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting. Lin J., Trocio J., Gupta K., Mardekian J., Lingohr-Smith M., Menges B., You M., Nadkarni A. 2017
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study. Lip GYH., Skjøth F., Nielsen PB., Kjældgaard JN., Larsen TB. 2017
Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation. Lee CJ., Pallisgaard JL., Olesen JB., Carlson N., Lamberts M., Gislason GH., Torp-Pedersen C., Brandes A., Husted SE., Johnsen SP., Hansen ML. 2017
Healthcare utilization and costs for patients initiating Dabigatran or Warfarin. Reynolds SL., Ghate SR., Sheer R., Gandhi PK., Moretz C., Wang C., Sander S., Costantino ME., Annavarapu S., Andrews G. 2017
Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin. Song X., Gandhi P., Gilligan AM., Arora P., Wang C., Henriques C., Sander S., Smith DM. 2017
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Coleman CI., Peacock WF., Bunz TJ., Alberts MJ. 2017
Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. Sjögren V., Byström B., Renlund H., Svensson PJ., Oldgren J., Norrving B., Själander A. 2017
Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies. Mueller T., Alvarez-Madrazo S., Robertson C., Bennie M. 2017
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Deitelzweig S., Luo X., Gupta K., Trocio J., Mardekian J., Curtice T., Lingohr-Smith M., Menges B., Lin J. 2017
Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation. Adeboyeje G., Sylwestrzak G., Barron JJ., White J., Rosenberg A., Abarca J., Crawford G., Redberg R. 2017
Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data. Brown JD., Shewale AR., Talbert JC. 2017
Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. Staerk L., Gerds TA., Lip GYH., Ozenne B., Bonde AN., Lamberts M., Fosbøl EL., Torp-Pedersen C., Gislason GH., Olesen JB. 2018
Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation. Hernandez I., Zhang Y., Saba S. 2017
Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. Borne RT., O'Donnell C., Turakhia MP., Varosy PD., Jackevicius CA., Marzec LN., Masoudi FA., Hess PL., Maddox TM., Ho PM. 2017
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. Norby FL., Bengtson LGS., Lutsey PL., Chen LY., MacLehose RF., Chamberlain AM., Rapson I., Alonso A. 2017
Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study. Denas G., Gennaro N., Ferroni E., Fedeli U., Saugo M., Zoppellaro G., Padayattil Jose S., Costa G., Corti MC., Andretta M., Pengo V. 2017
Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. Amin A., Keshishian A., Vo L., Zhang Q., Dina O., Patel C., Odell K., Trocio J. 2018
Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation. Deitelzweig S., Luo X., Gupta K., Trocio J., Mardekian J., Curtice T., Lingohr-Smith M., Menges B., Lin J. 2017
Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. Go AS., Singer DE., Toh S., Cheetham TC., Reichman ME., Graham DJ., Southworth MR., Zhang R., Izem R., Goulding MR., Houstoun M., Mott K., Sung SH., Gagne JJ. 2017
Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. Paciaroni M., Agnelli G., Falocci N., Tsivgoulis G., Vadikolias K., Liantinioti C., Chondrogianni M., Bovi P., Carletti M., Cappellari M., Zedde M., Ntaios G., Karagkiozi E., Athanasakis G., Makaritsis K., Silvestrelli G., Lanari A., Ciccone A., Putaala J., Tomppo L., Tatlisumak T., Abdul-Rahim AH., Lees KR., Alberti A., Venti M., Acciarresi M., D'Amore C., Becattini C., Mosconi MG., Cimini LA., Soloperto R., Masotti L., Vannucchi V., Lorenzini G., Tassi R., Guideri F., Acampa M., Martini G., Sohn SI., Marcheselli S., Mumoli N., De Lodovici ML., Bono G., Furie KL., Tadi P., Yaghi S., Toni D., Letteri F., Tassinari T., Kargiotis O., Lotti EM., Flomin Y., Mancuso M., Maccarrone M., Giannini N., Bandini F., Pezzini A., Poli L., Padovani A., Scoditti U., Denti L., Consoli D., Galati F., Sacco S., Carolei A., Tiseo C., Gourbali V., Orlandi G., Giuntini M., Chiti A., Giorli E., Gialdini G., Corea F., Ageno W., Bellesini M., Colombo G., Monaco S., Maimone Baronello M., Karapanayiotides T., Caso V. 2017
Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. Proietti M., Lip GYH. 2018
Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States. Jain R., Fu AC., Lim J., Wang C., Elder J., Sander SD., Tan H. 2018
Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System. Chrischilles EA., Gagne JJ., Fireman B., Nelson J., Toh S., Shoaibi A., Reichman ME., Wang S., Nguyen M., Zhang R., Izem R., Goulding MR., Southworth MR., Graham DJ., Fuller C., Katcoff H., Woodworth T., Rogers C., Saliga R., Lin ND., McMahill-Walraven CN., Nair VP., Haynes K., Carnahan RM. 2018
Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation. Hohnloser SH., Basic E., Hohmann C., Nabauer M. 2018
Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. Loo SY., Coulombe J., Dell'Aniello S., Brophy JM., Suissa S., Renoux C. 2018
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. Li X., Keshishian A., Hamilton M., Horblyuk R., Gupta K., Luo X., Mardekian J., Friend K., Nadkarni A., Pan X., Lip GYH., Deitelzweig S. 2018
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Shah S., Norby FL., Datta YH., Lutsey PL., MacLehose RF., Chen LY., Alonso A. 2018
Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. Wang SV., Huybrechts KF., Fischer MA., Franklin JM., Glynn RJ., Schneeweiss S., Gagne JJ. 2018
Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France. Collings SL., Vannier-Moreau V., Johnson ME., Stynes G., Lefèvre C., Maguire A., Asmar J., Bizouard G., Duhot D., Mouquet F., Fauchier L. 2018
Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Baruch L., Gage BF., Horrow J., Juul-Möller S., Labovitz A., Persson M., Zabalgoitia M. 2007
Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. Poli D., Testa S., Antonucci E., Grifoni E., Paoletti O., Lip GYH. 2011
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Friberg L., Rosenqvist M., Lip GY. 2012
Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Ruiz-Nodar JM., Marín F., Roldán V., Valencia J., Manzano-Fernández S., Caballero L., Hurtado JA., Sogorb F., Valdés M., Lip GY. 2012
Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Lip GY., Banerjee A., Lagrenade I., Lane DA., Taillandier S., Fauchier L. 2012
Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study. Bonde AN., Lip GY., Kamper AL., Fosbøl EL., Staerk L., Carlson N., Torp-Pedersen C., Gislason G., Olesen JB. 2016
Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. Haas S., Ten Cate H., Accetta G., Angchaisuksiri P., Bassand JP., Camm AJ., Corbalan R., Darius H., Fitzmaurice DA., Goldhaber SZ., Goto S., Jacobson B., Kayani G., Mantovani LG., Misselwitz F., Pieper K., Schellong SM., Stepinska J., Turpie AG., van Eickels M., Kakkar AK. 2016
Are Existing Risk Scores for Nonvalvular Atrial Fibrillation Useful for Prediction or Risk Adjustment in Patients With Chronic Kidney Disease? McAlister FA., Wiebe N., Jun M., Sandhu R., James MT., McMurtry MS., Hemmelgarn BR., Tonelli M. 2017
Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation. Jun M., James MT., Ma Z., Zhang J., Tonelli M., McAlister FA., Manns BJ., Ravani P., Quinn RR., Wiebe N., Perkovic V., Wilton SB., Winkelmayer WC., Hemmelgarn BR. 2017
Continued Use of Warfarin in Veterans with Atrial Fibrillation After Dementia Diagnosis. Orkaby AR., Ozonoff A., Reisman JI., Miller DR., Zhao S., Rose AJ. 2017
Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study. Renoux C., Coulombe J., Suissa S. 2017
Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System. An J., Niu F., Zheng C., Rashid N., Mendes RA., Dills D., Vo L., Singh P., Bruno A., Lang DT., Le PT., Jazdzewski KP., Aranda G. 2017
Effect of increased time in the therapeutic range on atrial fibrillation outcomes within a centralized anticoagulation service. Phelps E., Delate T., Witt DM., Shaw PB., McCool KH., Clark NP. 2018
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. Hylek EM., Go AS., Chang Y., Jensvold NG., Henault LE., Selby JV., Singer DE. 2003
Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Olesen JB., Lip GY., Lindhardsen J., Lane DA., Ahlehoff O., Hansen ML., Raunsø J., Tolstrup JS., Hansen PR., Gislason GH., Torp-Pedersen C. 2011
Dabigatran versus warfarin in patients with atrial fibrillation. Connolly SJ., Ezekowitz MD., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly PA., Themeles E., Varrone J., Wang S., Alings M., Xavier D., Zhu J., Diaz R., Lewis BS., Darius H., Diener HC., Joyner CD., Wallentin L. 2009
Oral anticoagulation in nonvalvular atrial fibrillation in clinical practice: impact of CHADS(2) score on outcome. Ruiz Ortiz M., Romo E., Mesa D., Delgado M., Anguita M., Castillo JC., Arizón JM., Suárez de Lezo J. 2010
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Bouillon K., Bertrand M., Maura G., Blotière PO., Ricordeau P., Zureik M. 2015
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Bousser MG., Bouthier J., Büller HR., Cohen AT., Crijns H., Davidson BL., Halperin J., Hankey G., Levy S., Pengo V., Prandoni P., Prins MH., Tomkowski W., Torp-Pedersen C., Thorp-Pedersen C., Wyse DG. 2008
An evaluation of the CHADS2 stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization Ruiz-Nodar JM, Marin F, Manzano-Fernandez S, et al 2011
Bleeding risk in 'real world' patients with atrial fibrillation: Comparison of two established bleeding prediction schemes in a nationwide cohort Olesen JB, Lip GYH, Hansen PR, et al 2011
Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation Lind M, Fahlen M, Kosiborod M, et al 2011
Transcatheter left atrial appendage closure in patients with atrial fibrillation Schmid M, Gloekler S, Saguner AM, et al 2013
Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin. Seeger JD., Bykov K., Bartels DB., Huybrechts K., Schneeweiss S. 2017
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Lip GY., Keshishian A., Kamble S., Pan X., Mardekian J., Horblyuk R., Hamilton M. 2016
Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study. Douros A., Renoux C., Coulombe J., Suissa S. 2017
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Amin A., Keshishian A., Trocio J., Dina O., Le H., Rosenblatt L., Liu X., Mardekian J., Zhang Q., Baser O., Vo L. 2017




Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: https://creativecommons.org/licenses/by-nc/3.0/